Omnicell, Inc. (NASDAQ:OMCL) announced its earnings results on Wednesday. The company reported $0.42 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.42, Bloomberg Earnings reports. The firm had revenue of $186.78 million for the quarter, compared to the consensus estimate of $192.45 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.40 EPS.
Shares of Omnicell (NASDAQ OMCL) traded down 0.55% on Thursday, hitting $53.95. The stock had a trading volume of 255,578 shares. The firm has a 50 day moving average of $50.92 and a 200-day moving average of $45.86. The firm’s market capitalization is $2.02 billion. Omnicell has a 1-year low of $30.35 and a 1-year high of $55.40.
Several research analysts have commented on OMCL shares. Dougherty & Co lifted their target price on Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Craig Hallum lifted their target price on Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $47.00 target price on shares of Omnicell in a report on Tuesday, July 25th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $55.00 target price on shares of Omnicell in a report on Thursday, October 19th. Finally, Benchmark Co. lifted their target price on Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a report on Tuesday, September 5th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Omnicell currently has an average rating of “Buy” and an average price target of $51.86.
In other news, Chairman Randall A. Lipps sold 40,000 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $49.76, for a total transaction of $1,990,400.00. Following the completion of the sale, the chairman now directly owns 196,551 shares in the company, valued at $9,780,377.76. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Peter J. Kuipers sold 3,532 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $50.96, for a total transaction of $179,990.72. Following the sale, the vice president now owns 40,714 shares of the company’s stock, valued at $2,074,785.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 184,094 shares of company stock valued at $9,094,791. 3.77% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Omnicell, Inc. (OMCL) Announces Quarterly Earnings Results” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/27/omnicell-inc-omcl-announces-quarterly-earnings-results.html.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.